Pyramiding of Meloidogyne hapla resistance genes in potato does not result in an increase of resistance

High levels of resistance against Meloidogyne hapla have been identified in wild species of tuber-bearing potatoes, but only QTL with partial effects have been identified so far in back crosses with cultivated potato. This study was designed to test if pyramiding of two previously identified resistance genes, R Mh-tar and R Mh-chc A, will result in improved or even an absolute level of resistance. R Mh-tar and R Mh-chc A introgressed from the wild tuber-bearing potato species Solanum tarijense and Solanum chacoense were combined in a segregating diploid Solanum tuberosum population. With the aid of AFLP markers, descendants from this segregating population were classified into four groups, carrying no R gene, with only R Mh-tar , with only R Mh-chc A and a group with the pyramided R Mh-tar and R Mh-chc A. Upon inoculation with M. hapla isolate Bovensmilde, the group containing only R Mh-chc A showed a decline of 88% in average number of developed egg masses compared to the group without R Mh-chc A and R Mh-tar . The group of genotypes containing only R Mh-tar , but not R Mh-chc A, showed a decline of 55% in the number of developed egg masses compared to the group without R Mh-chc A and R Mh-tar . Unfortunately, the latter effect of R Mh-tar was not significant. The effect of both loci, R Mh-tar and R Mh-chc A combined, did not further reduce the number of egg masses compared to the level of R Mh-chc A alon

Daily physical activity patterns in cancer survivors: a pilot study

In cancer survivors physical activity levels are measured primarily with questionnaires. As a result, insight in actual physical activity patterns of cancer survivors is lacking. Activity monitoring with accelerometers revealed that cancer survivors have lower levels of physical activity in the afternoon and early evening. This finding can help to personalize physical activity advice more adequately for these patients

Targeting the Beta-2-Adrenergic Receptor and the Risk of Developing Alzheimer's Disease:A Retrospective Inception Cohort Study

BACKGROUND: Animal studies suggested that β2-Adrenergic receptors (β2AR) may be a potential target for the treatment of Alzheimer's disease (AD). OBJECTIVE: This retrospective inception cohort study aimed to assess the association between antagonists and agonists of the β2AR and the risk of starting treatment for AD in older adults. METHODS: A retrospective inception cohort study was conducted among older adults who initiated either non-selective βAR antagonists or selective β2AR agonists using the University Groningen IADB.nl prescription database (study period 1994-2019). For each exposed cohort, two reference cohorts (A and B) were matched on age at index date. The main outcome was defined as at least two prescriptions for cholinesterase inhibitors (rivastigmine, galantamine, and donepezil) and/or memantine. Cox proportional hazard regression models were used to estimate hazard ratios (HR). RESULTS: The risk of developing AD was elevated among patients exposed to non-selective βAR antagonists (A: aHR 3.303, 95% CI 1.230-8.869, B: aHR 1.569, 95% CI 0.560-4.394) and reduced among patients exposed to selective β2AR agonists (A: aHR 0.049, 95% CI 0.003-0.795, B: aHR 0.834, 95% CI 0.075-9.273) compared to reference patients. CONCLUSION: These findings suggest that exposure to non-selective βAR antagonists is associated with an increased risk for developing AD whereas there may be a decreased risk for developing AD after exposure to selective β2AR agonists

Are processes in acceptance & commitment therapy (Act) related to chronic pain outcomes within individuals over time? : an exploratory study using n-of-1 designs

Acknowledgements The authors would like to thank the European Health Psychology Society for providing a grant that enabled the collaboration of the co-authors for this article. Author contributions HT designed the study, organized the data collection, carried out the statistical analyses and drafted the first version of the manuscript. DJ and MJ supervised the statistical analyses and were actively involved in writing and revising the manuscript. MVH and KS designed the study and were actively involved in writing and revising the manuscript. All authors read and approved the final manuscript.Peer reviewedPublisher PD

Biomarkers of the L-arginine / dimethylarginine / nitric oxide pathway in people with chronic airflow obstruction and obstructive sleep apnoea

Background: Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) are common chronic diseases that are associated with chronic and intermittent hypoxemia, respectively. Patients affected by the overlap of COPD and OSA have a particularly unfavourable prognosis. The L-arginine/nitric oxide (NO) pathway plays an important role in regulating pulmonary vascular function. Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) interfere with NO production. Methods: We analysed the serum concentrations of ADMA, SDMA, L-arginine, L-citrulline, and L-ornithine in a large sample of the Icelandic general population together with chronic airflow obstruction (CAO), a key physiological marker of COPD that was assessed by post-bronchodilator spirometry (FEV1/FVC 0.5. SDMA was significantly higher in individuals with CAO (0.518 [0.461–0.616] vs. 0.494 [0.441–0.565] µmol/L; p = 0.005), but ADMA was not. However, ADMA was significantly associated with decreasing FEV1 percent predicted among those with CAO (p = 0.002). ADMA was 0.50 (0.44–0.56) µmol/L in MAP ≤ 0.5 versus 0.52 (0.46–0.58) µmol/L in MAP > 0.5 (p = 0.008). SDMA was 0.49 (0.44–0.56) µmol/L versus 0.51 (0.46–0.60) µmol/L, respectively (p = 0.004). The highest values for ADMA and SDMA were observed in individuals with overlap of CAO and MAP > 0.5, which was accompanied by lower L-citrulline levels. Conclusions: The plasma concentrations of ADMA and SDMA are elevated in COPD patients with concomitant intermittent hypoxaemia. This may account for impaired pulmonary NO production, enhanced pulmonary vasoconstriction, and disease progression